IOBT News and Press, IO Biotech Inc. From 03/06/24

New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer va...

2024-03-06 03:39:01 ET More on IO Biotech IO Biotech: A Phase 3 Company Getting No Respect Seeking Alpha’s Quant Rating on IO Biotech Historical earnings data for IO Biotech Financial information for IO Biotech Read the full article on Seekin...

Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by ...

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO,...

2024-01-03 03:04:32 ET Summary IO Biotech is an immunotherapy biotech in phase 3 trials. Past failures of IDO as a target cast a pall on their potential data readouts. Nevertheless, the cheap stock price and upcoming catalysts make this an interesting play. Topline S...

NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win ® platform, announced today that the first patient has been dosed in its Phase 2 trial (NCT...

2023-11-28 08:35:36 ET More on pre-market losers stocks. Financial information for Green Giant Inc. Seeking Alpha’s Quant Rating on IO Biotech Historical earnings data for IO Biotech Financial information for IO Biotech For further details see:...

2023-11-27 11:24:36 ET More on IO Biotech Seeking Alpha’s Quant Rating on IO Biotech Historical earnings data for IO Biotech For further details see: IO Biotech executive discloses purchase of 10K shares

2023-11-13 13:25:28 ET More on IO Biotech Seeking Alpha’s Quant Rating on IO Biotech Historical earnings data for IO Biotech Financial information for IO Biotech For further details see: IO Biotech GAAP EPS of -$0.43 misses by $0.10

Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA ® (pembrolizumab), in patients with advanced melanoma Presented encouraging preliminary data from Phase 2 basket trial of IO102-IO103 at the ...